ERNAWErnexa Therapeutics Inc. Warrants
0.0564USD+12.35%Mkt Cap: —P/E: —3d ago
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.27M $
Revenue/Share—
Last Price0.0564 USD
Fiscal Year End—
MR Quarter—
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.02
EPS (TTM)—
EPS (Forward)—
52W Range
0.038016% of range0.1525
52W High0.1525 USD
52W Low0.0380 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-320.72%
ROA-105.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.84M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-4.68M $
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity10.91
Current Ratio2.01
Quick Ratio1.74
Book Value/Sh2.734 USD
Cash/Share3.080 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float1.22M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta2.56
S&P 52W Chg18.16%
Avg Vol (30d)15.77K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—